Literature DB >> 1738788

Different effects of serotonin (5-HT) uptake blockers in caudate nucleus and hippocampus of the rabbit: role of monoamine oxidase in dopaminergic terminals.

A Lupp1, K I Bär, C H Lücking, T J Feuerstein.   

Abstract

Slices of rabbit hippocampus or caudate nucleus were incubated with [3H]-5-HT (0.1 microM, 60 min) or with [3H]-DA. In hippocampal tissue, the 5-HT uptake blockers chlorimipramine, fluvoxamine, and 6-nitroquipazine (0.1, 1, 10 microM) reduced the percentage content of [3H]-5-HT in a concentration dependent manner. The degree of inhibition of [3H]-5-HT content produced by the 5-HT uptake inhibitors was not affected by the MAO inhibitors pargyline or amezinium (which by themselves enhanced [3H] loading) or the catecholamine uptake inhibitor nomifensine (which by itself did not affect [3H] loading). In caudate nucleus tissue, however, the [3H]-5-HT accumulation was reduced only at the highest concentration of the 5-HT uptake blockers (10 microM). In the additional presence of the MAO inhibitors or nomifensine (which by themselves increased or diminished, respectively, the [3H] labelling) the 5-HT uptake inhibitors became more potent in reducing the percentage [3H]-5-HT accumulation of caudate nucleus slices. These results indicate (1) that a false labelling of [3H]-5-HT into dopaminergic terminals in the caudate nucleus can be prevented by nomifensine, (2) that the 5-HT uptake blockers seem to accumulate within the dopaminergic terminals, where they may display a MAO inhibitory property. The 5-HT uptake blockers were ineffective on the percentage tritium accumulation of caudate nucleus slices incubated with [3H]-DA, regardless of the presence of pargyline or nomifensine. Tritiated DA and deaminated [3H]-metabolites were separated in the superfusate of [3H]-DA-release experiments in caudate nucleus tissue.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1738788     DOI: 10.1007/bf02253598

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  14 in total

1.  IMIPRAMINE IN TREATMENT OF PARKINSONISM: A DOUBLE-BLIND PLACEBO STUDY.

Authors:  R R STRANG
Journal:  Br Med J       Date:  1965-07-03

2.  Relationship between desipramine plasma levels and the effect in Parkinson's syndrome.

Authors:  G B Muscettola; M Giovannucci; R Montanini; P L Morselli; S Garattini
Journal:  Rev Eur Etud Clin Biol       Date:  1972-04

3.  Desipramine in treatment of Parkinson's disease. A placebo-controlled study.

Authors:  L Laitinen
Journal:  Acta Neurol Scand       Date:  1969       Impact factor: 3.209

4.  Effects of alpha-adrenoceptor antagonists on the release of serotonin and noradrenaline from rat brain cortex slices. Influence of noradrenaline uptake inhibition and determination of pA2 values.

Authors:  E Schlicker; M Göthert; F Köstermann; R Clausing
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-06       Impact factor: 3.000

5.  Fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor.

Authors:  V Claassen; J E Davies; G Hertting; P Placheta
Journal:  Br J Pharmacol       Date:  1977-08       Impact factor: 8.739

6.  Effect of amezinium on the release and catabolism of 3H-monoamines in brain slices.

Authors:  A Steppeler; C Döring; L Hedler; K Starke
Journal:  Biochem Pharmacol       Date:  1982-07-15       Impact factor: 5.858

7.  An in vitro model of 1-methyl-4-phenyl-pyridinium (MPP+) toxicity: incubation of rabbit caudate nucleus slices with MPP+ followed by biochemical and functional analysis.

Authors:  T J Feuerstein; L Hedler; R Jackisch; G Hertting
Journal:  Br J Pharmacol       Date:  1988-10       Impact factor: 8.739

8.  Du 24565, a quipazine derivative, a potent selective serotonin uptake inhibitor.

Authors:  W J Vaatstra; W M Deiman-Van Aalst; L Eigeman
Journal:  Eur J Pharmacol       Date:  1981-03-12       Impact factor: 4.432

9.  Imipramine hydrochloride (Tofranil) in Parkinsonism. A preliminary report.

Authors:  J C DENMARK; J D DAVID; S G McCOMB
Journal:  Br J Clin Pract       Date:  1961-06

10.  Endogenous noradrenaline as modulator of hippocampal serotonin (5-HT)-release. Dual effects of yohimbine, rauwolscine and corynanthine as alpha-adrenoceptor antagonists and 5-HT-receptor agonists.

Authors:  T J Feuerstein; G Hertting; R Jackisch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-05       Impact factor: 3.000

View more
  6 in total

1.  Presynaptic opioid receptors on noradrenergic and serotonergic neurons in the human as compared to the rat neocortex.

Authors:  Benjamin Berger; Anna Katharina Rothmaier; Franziska Wedekind; Josef Zentner; Thomas J Feuerstein; Rolf Jackisch
Journal:  Br J Pharmacol       Date:  2006-06-05       Impact factor: 8.739

2.  Differential inhibitory effects of drugs acting at the noradrenaline and 5-hydroxytryptamine transporters in rat and human neocortical synaptosomes.

Authors:  M Mantovani; D J Dooley; A Weyerbrock; R Jackisch; T J Feuerstein
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

Review 3.  Presynaptic control of serotonin on striatal dopamine function.

Authors:  Sylvia Navailles; Philippe De Deurwaerdère
Journal:  Psychopharmacology (Berl)       Date:  2010-10-16       Impact factor: 4.530

Review 4.  Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness.

Authors:  M I Wilde; G L Plosker; P Benfield
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

5.  Different effects of 1-methyl-4-phenyl-pyridinium (MPP+) on monoamine oxidase of dopaminergic terminals in caudate nucleus slices from pigmented and from albino rabbits.

Authors:  A Lupp; C H Lücking; L Hedler; T J Feuerstein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-02       Impact factor: 3.000

6.  Cannabinoid CB1 receptor-mediated modulation of evoked dopamine release and of adenylyl cyclase activity in the human neocortex.

Authors:  M Steffens; C Engler; J Zentner; T J Feuerstein
Journal:  Br J Pharmacol       Date:  2004-03-01       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.